請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36493完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 莊立民(Lee-Ming Chuang) | |
| dc.contributor.author | Yi-Der Jiang | en |
| dc.contributor.author | 江怡德 | zh_TW |
| dc.date.accessioned | 2021-06-13T08:02:54Z | - |
| dc.date.available | 2006-08-03 | |
| dc.date.copyright | 2005-08-03 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-07-22 | |
| dc.identifier.citation | 1. Criqui MH, Fronek A, Barret-Connor E, Klauber MR, Gabriel S. The prevalence of peripheral arterial disease in a defined population. Circulation 71: 510- 515, 1985
2. Ogren M, Hedblad B, Isacsson SO, Janzon L, Jungquist G, Lindell SE. Ten year cerebrovascular morbidity and mortality in 68 year old men with asymptomatic carotid stenosis. BMJ 310: 1294-8, 1995 3. Leng GC, Fowkes FGR, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 313:1440-1444, 1996 4. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 270: 465-469, 1993 5. Beach KW, Bedford GR, Bergelin RO, Martin DC, Vandenberghe N, Zaccardi M, Strandness DE Jr. Progression of lower-extremity arterial occlusive disease in type 2 diabetes mellitus. Diabetes Care 11: 464-472, 1998 6. Katsilambros NL, Tsapogas PC, Arvanitis MP, Tritos NA, Alexiou ZP, Rigas KL: Risk factors for lower-extremity arterial disease in non-insulin-dependent diabetic persons. Diabet Med 13: 243-246, 1996 7. Beks PJ, MacKaay AJ, de Neeling JN, et al. Peripheral arterial disease in relation to glycemic level in an elderly Caucasian population: the Hoorn study. Dibetologia 38: 86-96, 1995 8. Premalatha G, Shanthirani S, Deepa R, Markovitz J, Mohan V. Prevalence and risk factors of peripheral vascular disease in a selected south India population. Diab Care 23: 1295-1300, 2000 9. Reunanen A, Takkenen H, Aroma A: Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 211: 249-256, 1982 10. Jelnes R, Gaardsting O, Hougaard-Jensen K, Baekgaard N, Tonnesen KH, Schroeder T: Fate in intermittent claudication: Outcome and risk factors. Br Med J 293: 1137-1140, 1986 11. Criqui MH, Coughlin SS, Fronek A: Non-invasive diagnosed peripheral arterial disease as a predictor of mortality: Results from a prospective population-based study. Circulation 72: 768-773, 1985 12. Howell MA, Colgan MP, Seeger RW, Ramsey DE, Sumner DS. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: A six-year follow-up study. J Vasc Surg 9: 691-7, 1989 13. Vogt MT, McKenna M, Anderson SJ, Wolfson SK, Kuller LH. The relationship between ankle-arm index and mortality in older men and women. J Am Geriatr Soc 41: 523-530, 1993 14. Kornitzer M, Dramaix M, Sobolski J, Degre S, De Backer G. Ankle/arm pressure index in asymptomatic middle-aged males: An independent predictor of ten-year coronary heart disease mortality. Angiology 46: 211-219, 1996 15. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326: 381-6, 1992 16. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin dependent diabetes mellitus. The Finnish Studies. Ann Intern Med 124: 127-130, 1996 17. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. Diabetes Care 21: 1167-1173, 1998 18. Rose GA: The diagnosis of ischemic heart pain and intermittent claudication in field survey. Bull WHO 27: 645-658, 1962 19. Criqui MH, Fronek A, Klauber MR, Barret-Connor E, Gabriel S: The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral artery disease: Results from a non-invasive testing in a defined population. Circulation 71: 516-521, 1985 20. Boyko EJ, Ahroni JH, Davignon D, Stensel V, Prigeon RL, Smith DG. Diagnostic utility of the history and physical examination for peripheral vascular disease among patients with diabetes mellitus. J Clin Epidemiol 50: 659-668, 1997 21. American Diabetes Association. Peripheral arterial disease in people with diabetes:Diab Care 26: 3333-41, 2003 22. Adler AI, Steven RJ, Neil A, Strtton IM, Boulton AJ, Holman RR. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diab Care 25: 894-899, 2002 23. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication and risk of cardiovascular events. The Framingham Study. Diabetes 38:504–9, 1989 24. Dormandy J, Heeck L, Vig S. Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg 12:138– 41, 1999 25. Criqui MH, Browner D, Fronek A, Klauber MR, Caughlin SS, Barrett-Connor E, Gabriel S. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease: an analysis of risk factors. Am J Epidemiol 129:1110–9, 1989 26. Price JF, Lee AJ, Fowkes FG. Hyperinsulinemia: a risk factor for peripheral arterial disease in a non diabetic general population. J Cardiovasc Risk 3:501– 5, 1996 27. Kannel WB, Shurleff D. The Framingham Study. Cigarettes and the development of intermittent claudication. Geriatrics 28:61 –8, 1973 28. Murabito JM, D’Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication: a risk profile from the Framingham heart study. Circulation 96:44– 9,1997 29. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Ruckley CV. Smoking, lipids, glucose intolerance and blood pressure as risk factor for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 135:331– 340, 1992 30. Ingolfsson IO, Sigurdsson G, Sigraldoson H, Thorgeirsson G, Sigfusson N. A marked decline in the prevalence and incidence of intermitten claudication in leelandic men 1968– 1986: a strong relationship to smoking and serum cholesterol. The Reykjavik Study. J Clin Epidemiol 47:1237– 43, 1994 31. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 221: 253– 60, 1987 32. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking and associated with dose-related and potentially reversible impairment of endothelium dependent dilation in healthy young adults. Circulation 88:2149– 55, 1993 33. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med 1:60– 4, 1996 34. Hooi JD, Kestes AD, Stoffers HE, Overdijk MM, Von Rec JW, Knottners JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 153:666– 72, 2001 35. Kannel WB, Skinner JJ, Schwartz MJ, Shurtleff D. Intermittent claudication:incidence in the Framingham study. Circulation 41:875– 83, 1970 36. Zimmerman BR, Palumbo PJ, Fallon WM, Ellefson RD, Osmundson PJ, Kazmier FJ. A prospective study of peripheral occlusive arterial disease in diabetes: III. Initial lipid and lipoprotein findings. Mayo Clinic Proc 56:233– 42, 1981 37. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA, J Am Med Assoc 274:1049– 57, 1995 38. Smith FB, Lowe GD, Lee AJ, Romley A, Leng GC, Fowkes FG. Smoking, hemoreologic factors, and progression of peripheral arterial disease in patients with claudication. J Vasc Surg 28:129– 35, 1998 39. Philipp CS, Cisar LA, Kim HC, Wilson AC, Saidi P, Kostis JB. Association of hemostatic factors with peripheral vascular disease. Am Heart J 134:978– 84, 1997 40. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S,Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999 41. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T,Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel adipose-specific protein,adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000 42. Yang YS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Plasma adiponectin levels in overweight and obese Asians. Obes Res 10: 1104-1110, 2002 43. Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang YS. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab 88: 4130-4134, 2003 44. Shurk T, Van Harmelen V, Lee YM, Wirth A, Hauner H. Relationship between IL-6, Leptin and Adiponectin and Variables of Fibrinolysis in Overweight and Obese Hypertensive Patients. Horm Metab Res 34: 659-663, 2002 45. Engeli S, Feldpausch M, Gorzelnaik K, Hartwig F, Heintze U, Janke J, Mohlig M,Pfeiffer AF, Luft FC, Sharma AM. Association between adiponectin and mediators of inflammation in obese women. Diabetes 52: 942-947, 2003 46. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 88: 2714-2718, 2003 47. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in Pima Indian. Diabetes Care 26:1745-1751, 2003 48. Matsubara M, Namioka K, Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol 148: 657-662, 2003 49. Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107: 671-674, 2003 50. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, Ueda S, Shimomura I, Funahashi T, Matsuzawa Y. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endicrinol Metab 88: 3236-3240, 2003 51. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Matsuzawa Y. Arterioscler Thromb Vasc Biol 23: 85-89, 2003 52. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamato Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte- derived plasma protein adiponectin. Circulation 100: 2473-2476, 1999 53. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani J, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8; 731-737, 2002 54. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-1732, 2000 55. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057-1063,2001 56. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 27:27, 2003 57. Klein R, Klein BE, Moss SE, Davis MD. Demets DL. The Wisconsin epidemiology study of diabetic retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmology 102:527-32, 1984 58. American Diabetes Association. Eye care guidelines for patients with diabetes mellitus. Diab Care 11:745-746, 1988 59. DeFronzo RA. Diabetic nephropathy: etiological and therapeutic consideration. Diabetes Rev 3:510-514, 1995 60. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995 61. American Diabetes Association. Diabetic Nephropathy. Diab Care 20: suppl1:s24-s27, 1997 62. American Diabetes Association. Diabetic neuropathies. Diab Care 28: 956-962,2005 63. Jiang YD, Chuang LM, Wu HP, Tai TY, Lin BJ. Role of an outpatient clinic in screening chronic complications of diabetes: a model for diabetes managed care. J Formos Med Assoc. 97: 521-7, 1998 64. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 352(9131):854-65, 1998 65. Jiang YD, Yen CJ, Chou WL, Kuo SS, Lee KC, Chiu KC, Chunag LM. Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in Type 2 diabetic subjects. Diabet Med 2005 (in press) 66. Tseng CH. Prevalence and risk factors of peripheral arterial obstructive disease in Taiwanese type 2 diabetic patients. Angiology 54:331-8, 2003 67. Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL, Hirsch AT Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 180: 389-397, 2005 68. Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial calcification and diabetic neuropathy. Br Med J 284:928-930, 1982 69. Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 36:615-621, 1993 70. Orchard TJ, Strandess DE Jr, Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by American Diabetes Association and American Heart Association. 18-20 Sep 1992, New Orleans, Louisiana. Circulation 88:819-828, 1993 71. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, Howard BV. Relationship of High and Low Ankle Brachial Index to All-Cause and Cardiovascular Disease Mortality. The Strong Heart Study. Circulation 109:733-739, 2004 72. Resnick HE. Foster GL. Prevalence of elevated ankle-brachial index in the United States 1999 to 2002. Am J Med 118:676-679, 2005 73. Salmenniemi U, Zacharova J, Ruotsalainen E et al. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 90:4216-4623, 2005. 74. Tsou PL, Jiang YD, Chang CC, Wei JN, Sung FC, Lin CC, Chiang CC, Tai TY, Chuang LM. Sex-Related Differences Between Adiponectin and Insulin Resistance in Schoolchildren. Diab Care 27: 308-313, 2004. 75. Wei JN, Chuang LM, Lin CC, Chiang CC, Lin RS, Sung FC. Childhood diabetes identified in mass urine screening program in Taiwan, 1993-1999. Diab Res Clin Pract 59: 201-206, 2003. 76. Soderberg S, Stegmayr B, Stenlund H, Sjostrom LG, Agren A, Johansson L, Weinehall L, Olsson T. Leptin, but not adiponectin, predicts stroke in males. J Intern Med. 256128-36, 2004. 77. Kumada M. Kihara S. Sumitsuji S. Kawamoto T. Matsumoto S. Ouchi N. Arita Y. Okamoto Y. Shimomura I. Hiraoka H. Nakamura T. Funahashi T. Matsuzawa Y. Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arteriosclerosis, Thrombosis & Vascular Biology. 23:85-9, 2003. 78. Lacquemant C. Froguel P. Lobbens S. Izzo P. Dina C. Ruiz J. The adiponectin gene SNP+45 is associated with coronary artery disease in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetic Medicine. 21:776-81, 2004. 79. Dzielinska Z. Januszewicz A. Wiecek A. Demkow M. Makowiecka-Ciesla M. Prejbisz A. Kadziela J. Mielniczuk R. Florczak E. Janas J. Januszewicz M. Ruzyllo W. Decreased plasma concentration of a novel anti-inflammatory protein--adiponectin--in hypertensive men with coronary artery disease. Thrombosis Research. 110:365-9, 2003. 80. Ohashi K. Ouchi N. Kihara S. Funahashi T. Nakamura T. Sumitsuji S. Kawamoto T. Matsumoto S. Nagaretani H. Kumada M. Okamoto Y. Nishizawa H. Kishida K. Maeda N. Hiraoka H. Iwashima Y. Ishikawa K. Ohishi M. Katsuya T. Rakugi H. Ogihara T. Matsuzawa Y. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. Journal of the American College of Cardiology. 43:1195-200, 2004. 81. Ouchi N. Kihara S. Funahashi T. Nakamura T. Nishida M. Kumada M. Okamoto Y. Ohashi K. Nagaretani H. Kishida K. Nishizawa H. Maeda N. Kobayashi H. Hiraoka H. Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 107:671-4, 2003. 82. Qi L, Li T, Rimm E, Zhang C, Rifai N, Hunter D, Doria A, Hu FB.The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes. 54:1607-10, 2005. 83. Krakoff J, Funahashi T, Stehouwer CDA, Schalkwijk CG,Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima India. Diabetes Care 26: 1745, 2003. 84. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indian. Diabetes Care 26: 3226, 2003. 85. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:725-734, 1997. 86. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International, 63:225–232, 2003. 87. Looker HC, Bennett PH, Krakoff J, Klein R, Knowler WC, Hanson RL. Longitudinal studies of incidence and progression of diabetic retinopathy assessed by retinal photography in Pima Indians. Diab Care 26:320-326, 2003. 88. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. NEJM 348: 2285-93, 2003 89. Nolting PR. de Groot E. Zwinderman AH. Buirma RJ. Trip MD. Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 163:1837-41,2003. 90. Matsuzaki M. Hiramori K. Imaizumi T. Kitabatake A. Hishida H. Nomura M. Fujii T. Sakuma I. Fukami K. Honda T. Ogawa H. Yamagishi M. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). Journal of the American College of Cardiology. 40:220-7, 2002. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36493 | - |
| dc.description.abstract | Aim:
The main purpose of this study is to explore the natural history of peripheral arterialdisease (PAD) in type 2 diabetes, including prevalence, incidence, mortality, risk factors and potential regression. Study design and methods: A clinic for screening diabetic complications has been set up since July 1996. Till Dec 2002, 3,632 type 2 diabetic patients were referred for a baseline screening. Among them, there were 1,577 subjects were followed with a baseline ABI>0.9 and were analyzed for incidence of PAD. Among the patients for incidence study, there were 344 cases over 60 years old with adiponectin data. The effect of adiponectin level on PAD incidence was further analyzed. Age, sex, duration of diabetes, hemoglobin A1c, systolic/diastolic blood pressure, triglyceride, total cholesterol, smoking, exercise, body mass index, college education were also obtained and analyzed with Students t-test, Chi-square (or Fisher’s exact test), and correlations. Logistic regression, Cox regression.and Monte Carlo Markov Chain method were used for the analyses of the risk factors of prevalence and incidence, and progression and/or regression for the natural history of PAD among type 2 diabetes. P below 0.05 was considered statistic significance. Results: The prevalence of PAD was 5.95 % in a group of type 2 diabetes with a mean duration of 9.02 ± 8.00 years. The incidence was estimated at 1.14 % per year during 4.24 ± 2.08 years of follow-up. ABI > 1.4 or ABI < 0.9 were ndependent risk factors for all-cause and cardiovascular mortality in subjects with type 2 diabetes. Old age, smoking, poor glycemic or blood pressure control, dyslipidemia were significant risk factors for PAD prevalence, incidence, and mortality (for ABI between 0.9 and 1.4). Hypoadiponectinemia (<3.75 μg/ml) was associated with new PAD onset for those aged over 60. Incident cases, mild PAD (ABI 0.7~0.9 vs. < 0.7), and better blood pressure control, higher education level, and higher BMI were salutary factors for regression of PAD. Conclusion: Ankle-brachial index (ABI) is still a good, if not the best, screening tool for peripheral arterial disease in type 2 diabetic patients. Abnormal ABI, either below 0.9 or above 1.4, is associated with a significantly higher all-cause or cardiovascular mortality in patients with type 2 diabetes. Age is the strongest factor for abnormal ABI and mortality. Among the modifiable risk factors, glycemic, lipid and blood pressure control are important to prevent new PAD. Moreover, once a low ABI is detected, aggressive treatment should be instituted because one third or more patients might have a chance to return normal ABI before they progress to a severer degree of PAD with ABI<0.7. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T08:02:54Z (GMT). No. of bitstreams: 1 ntu-94-D89842009-1.pdf: 1340737 bytes, checksum: ca0385062c3b0abf38676500550ae257 (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 摘要 3
壹、研究緣起 5 貳、文獻探討 一、 周邊動脈疾病之流行病學 7 二、 周邊動脈疾病發生率之危險因子 8 三、 脂締素與周邊動脈疾病 9 參、研究目的 11 肆、研究方法 一、研究架構 12 二、周邊動脈疾病之流行病學 13 三、周邊動脈疾病發生率之危險因子 14 四、脂締素與周邊動脈疾病 14 伍、研究結果 15 六、討論 23 七、參考文獻 31 Appendix 43 | |
| dc.language.iso | en | |
| dc.subject | 第二型糖尿病 | zh_TW |
| dc.subject | 周邊動脈疾病 | zh_TW |
| dc.subject | 台灣 | zh_TW |
| dc.subject | Taiwan | en |
| dc.subject | peripehral arterial disease | en |
| dc.subject | Type 2 diabetes mellitus | en |
| dc.title | 第二型糖尿病患之周邊動脈疾病之研究 | zh_TW |
| dc.title | Peripheral arterial disease among type 2 diabetic patients:
From cross-sectional to longitudinal prospective studies | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.coadvisor | 陳秀熙(Hsui-Hsi Chen) | |
| dc.contributor.oralexamcommittee | 林瑞祥(Boniface J. Lin),戴東原(Tony-Yuan Tai),張淑惠(Shu-Hui Chang) | |
| dc.subject.keyword | 第二型糖尿病,周邊動脈疾病,台灣, | zh_TW |
| dc.subject.keyword | Type 2 diabetes mellitus,peripehral arterial disease,Taiwan, | en |
| dc.relation.page | 79 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-07-22 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 未授權公開取用 | 1.31 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。